Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is on recovery track with 70.67% gain from a 1-year low price of $4.5. The company added 5.49% to attain the price of $7.68 on 02/08/2019. Throughout the recent session, the prices were hovering between $7.2236 and $7.74. These shares are 208.72% off its target price of $23.71 and the current market capitalization stands at $456.04M. The recent change has given its price a 11.17% lead over SMA 50 and -10.39% deficit over its 52-week high. The stock witnessed -0.26% declines, 5.21% gains and 65.16% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CRBP’s volatility during a week at 6.35% and during a month it has been found around 6.21%.Corbus Pharmaceuticals Holdings, Inc. (CRBP) Top Holders
Institutional investors currently hold around $200 million or 42.1% in CRBP stock. Look at its top three institutional owners. Blackrock Inc. owns $39.47 million in Corbus Pharmaceuticals Holdings, Inc., which represents roughly 8.66% of the company’s market cap and approximately 19.74% of the institutional ownership. Similar statistics are true for the second largest owner, Knoll Capital Management, Lp, which owns 4,062,791 shares of the stock are valued at $31.2 million. The third largest holder is Etf Managers Group, Llc, which currently holds $30.4 million worth of this stock and that ownership represents nearly 6.67% of its market capitalization.Corbus Pharmaceuticals Holdings, Inc. 13F Filings
At the end of December reporting period, 40 institutional holders increased their position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by some 5,634,389 shares, 35 decreased positions by 3,354,806 and 18 held positions by 17,110,743. That puts total institutional holdings at 26,099,938 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 4,727,129 shares while 12 institutional investors sold out their entire positions totaling 611,861 shares.Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Insider Trades
Multiple company employees have indulged in significant insider trading. Corbus Pharmaceuticals Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer White Barbara has acquired 2,586 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) in trading session dated May. 15, 2018. These shares are worth $15,180 and were traded at $5.87 each. The SEC filing shows that Cohen Yuval performed a purchase of 1,725 shares. The CEO added these shares by way of transaction on May. 15, 2018. The company’s shares were assimilated at $5.85 per share worth to an investment of some $10,091 on account of Cohen Yuval.
CFO, Moran Sean F., purchased 4,000 common shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the open market. In a transaction dated May. 15, 2018, the shares were bought at an average price of $5.77, giving away a sum of $23,080. After this purchase, 348,010 common shares of CRBP are directly owned by the insider, with total stake valued at $2,672,717.
In the transaction dated May. 14, 2018, the great number of shares acquired came courtesy the Director; Hochman David P added a total of 5,000 shares at an average price of $5.48, amounting to approximately $27,400. The insider now directly owns 702,400 shares worth $5,394,432.Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analyst Guide
Several analysts have released their opinion on Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 8 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.